Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Status:
Terminated
Trial end date:
2016-09-26
Target enrollment:
Participant gender:
Summary
Acute Graft Versus Host Disease (GVHD) is a serious medical condition that is a common
development after Bone Marrow Transplant (BMT). Acute GVHD happens when the donor cells
attack and damage your tissues and organs after transplant.
Acute GVHD often causes: Skin rashes, nausea, vomiting, abdominal pain, diarrhea (may have
blood), liver damage that can cause inflammation in the liver or jaundice (yellowing of the
skin or eyes), damage to other organs
Steroids are the first line of treatment for acute GVHD. About a quarter of the patients that
develop acute GVHD may not respond to steroid and have steroid refractory GVHD (SR-aGVHD).
Patients with SR-aGVHD may need other medications. SR-aGVHD, is a potentially life
threatening condition. There is no standard treatment and it may not respond to treatment.
The goals of this study are to find out if Infliximab and basiliximab can treat SR-aGVHD.
Participants in this study will receive combination therapy (2 drugs: infliximab and
basiliximab) once a week for four weeks.